Literature DB >> 35867293

The potential role of circulating exosomes in protecting myocardial injury in acute myocardial infarction via regulating miR-190a-3p/CXCR4/CXCL12 pathway.

Chun-Yuan Jiang1, Ting-Ting Zhong2, Lu-Wen Qiu3, Yan-Feng Liu1, Hui-Hua Zuo3, Xiao-Fei Huang1.   

Abstract

Exosomes of different origins have been found to be protective against ischemic-induced myocardial injury. This study examined the protective effects of circulating exosomes in the mice model of acute myocardial infarction (AMI) and explored the underlying molecular mechanisms. The effects of exosomes on myocardial injury were assessed in the AMI mice model. The in vivo studies showed that circulating exosomes reduced the infarcted size, improved the morphology of heart tissues and also reduced apoptosis of the heart tissues. In addition, the model mice showed an increase in the CD34 + /VEGFR2 + cell population and CD31, CXCR4 and CXCL12 expression after exosomes treatment. MiR-190a-3p was significantly down-regulated in the exosomes derived from the culture medium of hypoxia-treated human cardiomyocytes (HCMs). Further analysis revealed that miR-190a-3p could physically interact with CXCR4/CXCL12 by targeting the respective 3'UTRs. These exosomes could up-regulated CXCR4 and CXCL12 expression in the EPCs; in addition, miR-190a-3p mimics repressed CXCR4/CXCL12 expression in EPCs, while its inhibitor had opposite effects. The in vitro functional assays showed that miR-190a-3p overexpression suppressed the cell viability, proliferation, migration, adhesion and tube formation of EPCs; while miR-190a-3p inhibitor had the opposite effects; exosomes derived from the culture medium of hypoxia-treated HCMs exhibited similar actions of miR-190a-3p inhibitor. Moreover, miR-190a-3p was down-regulated in exosomes from serum in the AMI group when compared to that from sham group. Treatment with exosomes from serum in the AMI group promoted cell proliferation, migration, adhesion and tube formation of EPCs when compared to that in the sham group. More importantly, IT1t attenuated the enhanced effects of miR-190a-3p inhibition on EPC proliferation, migration, adhesion and tube formation. In conclusion, circulating exosomes exerted protective effects on myocardial injury in the AMI mice model, and down-regulation of miR-190a-3p in the circulating exosomes may exert protective effects against myocardial injury. Hypoxia induced the downregulation of miR-190a-3p in the culture medium of HCMs, and the mechanistic investigations indicated that exosomes of hypoxia-conditioned HCM culture medium promoted the cell viability, proliferation, migration, adhesion and tube formation of EPCs via regulating miR-190a-3p/CXCR4/CXCL12 pathway.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Acute myocardial infarction; CXCL12; CXCR4; EPCs; Exosomes; miR-190a-3p

Mesh:

Substances:

Year:  2022        PMID: 35867293     DOI: 10.1007/s10863-022-09944-5

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   3.853


  32 in total

1.  CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities.

Authors:  Erik B Friedrich; Katrin Walenta; John Scharlau; Georg Nickenig; Nikos Werner
Journal:  Circ Res       Date:  2006-01-26       Impact factor: 17.367

2.  Circulating exosomes repair endothelial cell damage by delivering miR-193a-5p.

Authors:  Chang Cao; Bo Wang; Junnan Tang; Jimin Zhao; Jiacheng Guo; Qianqian Guo; Xiaoting Yue; Zenglei Zhang; Gangqiong Liu; Hui Zhang; Yunzhe Wang; Jinying Zhang
Journal:  J Cell Mol Med       Date:  2020-12-22       Impact factor: 5.310

Review 3.  Acute Myocardial Infarction.

Authors:  Jeffrey L Anderson; David A Morrow
Journal:  N Engl J Med       Date:  2017-05-25       Impact factor: 91.245

Review 4.  Acute Complications of Myocardial Infarction in the Current Era: Diagnosis and Management.

Authors:  Anurag Bajaj; Ankur Sethi; Parul Rathor; Nissi Suppogu; Arjinder Sethi
Journal:  J Investig Med       Date:  2015-10       Impact factor: 2.895

5.  Enhanced adhesive properties of endothelial progenitor cells (EPCs) in patients with SLE.

Authors:  Jacob N Ablin; Viktoria Boguslavski; Valerie Aloush; Ori Elkayam; Daphna Paran; David Levartovski; Dan Caspi; Jacob George
Journal:  Rheumatol Int       Date:  2010-03-07       Impact factor: 2.631

Review 6.  Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy.

Authors:  Vanessa Bianconi; Amirhossein Sahebkar; Petri Kovanen; Francesco Bagaglia; Biagio Ricciuti; Paolo Calabrò; Giuseppe Patti; Matteo Pirro
Journal:  Pharmacol Ther       Date:  2017-08-19       Impact factor: 12.310

Review 7.  Predicting death after acute myocardial infarction.

Authors:  Yulanka Castro-Dominguez; Kumar Dharmarajan; Robert L McNamara
Journal:  Trends Cardiovasc Med       Date:  2017-08-02       Impact factor: 6.677

Review 8.  The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease.

Authors:  Yvonne Döring; Lukas Pawig; Christian Weber; Heidi Noels
Journal:  Front Physiol       Date:  2014-06-11       Impact factor: 4.566

9.  Circulating myocardial microRNAs from infarcted hearts are carried in exosomes and mobilise bone marrow progenitor cells.

Authors:  Min Cheng; Junjie Yang; Xiaoqi Zhao; Eric Zhang; Qiutang Zeng; Yang Yu; Liu Yang; Bangwei Wu; Guiwen Yi; Xiaobo Mao; Kai Huang; Nianguo Dong; Min Xie; Nita A Limdi; Sumanth D Prabhu; Jianyi Zhang; Gangjian Qin
Journal:  Nat Commun       Date:  2019-02-27       Impact factor: 14.919

10.  Cardiomyocyte-derived small extracellular vesicles can signal eNOS activation in cardiac microvascular endothelial cells to protect against Ischemia/Reperfusion injury.

Authors:  Guihao Chen; Chuansheng Xu; Thomas G Gillette; Tongyi Huang; Peisen Huang; Qing Li; Xiangdong Li; Qinfeng Li; Yu Ning; Ruijie Tang; Cunrong Huang; Yuyan Xiong; Xiaqiu Tian; Jun Xu; Junyan Xu; Liping Chang; Cong Wei; Chen Jin; Joseph A Hill; Yuejin Yang
Journal:  Theranostics       Date:  2020-09-23       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.